Treatment of T-Cell Prolymphocytic Leukemia with Central Nervous System Involvement Using Intrathecal Alemtuzumab Administration

<div>Treatment time course for the leukemia and central nervous system involvement. ALM: alemtuzumab; CSF: cerebrospinal fluid; FC: fludarabine and cyclophosphamide; HSCT: hematopoietic stem-cell transplantation; IT: intrathecal treatment; IV: intravenous treatment; MTX: methotrexate; WBI: whole brain irradiation; and WSI: whole spine irradiation. Triplets consist of 15 mg of methotrexate, 40 mg of cytarabine, and 20 mg of prednisolone.</div>

Case Reports in Hematology

fig2

Figure 2

Figure 2: Treatment of T-Cell Prolymphocytic Leukemia with Central Nervous System Involvement Using Intrathecal Alemtuzumab Administration 